The AR has been shown to increase glucose uptake in LNCaP cells [9,10], which is in line with clinical observations in patients undergoing cancer screening using 18F-fluorodeoxyglucose (a glucose analog that is taken up by metabolically active tumor cells) through positron emission tomography/computed tomography. This evidence concerns the gene AR and neoplasm.